Phosphodiesterase Enzyme (PDE) Inhibitors Market becomes an investment hotspot after getting aroused by an elevated occurrence of erectile dysfunction

 

In March 2021, a group of researchers from Karolinska Institute, Stockholm, Sweden concluded the results of their clinical study claiming that the use of PDE5 (Phosphodiesterase type-5) inhibitor in treatment of erectile dysfunction can lower the occurrence of cardiovascular disorders. Additionally, in July 2021, the bio-pharmaceutical company, Arcutis Biotherapeutics, Inc., enrolled the first patient in its Phase III clinical trial on ARQ-154 for treatment of seborrheic dermatitis.

Phosphodiesterase inhibitors are highly effective in combating the adverse effects of Crohn's disease. Enzymes that prevent or regulate the action of Crohn's Disease in the intestines to prevent inflammation and promote the healthy functioning of the intestine. Various proprietary anti-inflammatory (NSAIDs) in the market today are effective in reducing pain and swelling associated with Crohn's and improving the patient's quality of life. Some NSAIDs inhibit the absorption of substances like fatty acids, cholesterol and phospholipids. Oral non-steroidal anti-inflammatory drugs (USIDs) like Aspirin, Ibuprofen and Naproxen are the commonly used NSAIDs for Crohn's disease.

Crohn's and ulcerative colitis are very common inflammatory bowel diseases affecting the large colon. Crohn's affects the lower portion of the small intestine and causes ulcers within the colon. Ulcerative colitis is an inflammatory bowel disease causing inflammation of the colon. Crohn's and ulcerative colitis are affected by a variety of gastrointestinal (GI) medications including sulfasalazine, balsalazide and vincristine.

Besides these two serious inflammatory bowel diseases, there are a number of other conditions that respond well to the use of inhibitors. Non-alcoholic steatohepatitis (NASH) is a condition where the protective mucus layer in the stomach is replaced with a villous lining from the outside of the body.

Rising drug abuse cases are leading to a surge in erectile dysfunction (ED) conditions in men amidst changing lifestyles, which, in turn, are creating positive growth prospects for the phosphodiesterase enzyme (PDE) inhibitors market. Plus, the amalgamation of factors such as hyperlipidemia, prostate cancer, high blood pressure, diabetes, testosterone insufficiency, and overweight is broadening the scope for the phosphodiesterase enzyme (PDE) inhibitors market. On the contrary, the complications associated with PDE inhibitors along with the advent of generic drugs can cause a serious dent in the progress of the phosphodiesterase enzyme (PDE) inhibitors market.

Throughout the globe, the phosphodiesterase enzyme (PDE) inhibitors market in the North American region is likely to propel at a scalable rate on the heels of rising incidences of chronic disease coupled with the increased healthcare expenditure. In parallel, the Asia Pacific is also proving to be fruitful for the phosphodiesterase enzyme (PDE) inhibitors market owing to the growing number of erectile dysfunction cases compounded with the hormonal deficiencies among the population.

Off-road Vehicles are becoming increasingly popular for recreational activities, camping, and sight-seeing in distant locations from pavement

 

An off-road vehicle in the simplest definition can be defined as any kind of vehicle that is able to drive off-road and that too on and off the paved or rugged terrain. It is usually characterized by having deep, wide tires with open, deep treads, flexible suspensions, or even hydraulic tracks. The traction on such off-road vehicles is usually quite good. However, the terrain they are driven on may not always be easy, smooth, and safe.

As far as off-road vehicles are concerned, different suspension designs are applied for them. The most common types of suspension design used on such vehicles are truck-mounted, four-wheel drive, and two-wheel drive. These days, a lot of car and truck manufacturers are developing high-performance four-wheel drive and two-wheel drive designs of off-road vehicles. These designs, however, use high-performance shocks with better ball joints and springs for optimal suspension performance. In fact, many automobile enthusiasts who are looking to build their own off-road vehicles choose to incorporate such components in their vehicles.

High-performance shock absorbers and springs help the engine to function better when the tires are under rough conditions. Good off-road vehicles usually have high ground clearance. The clearance should be at least 18 inches; in some instances, it is even preferred to have a clearance of up to 24 inches. This is to ensure the vehicle has adequate space to maneuver over uneven and loose surfaces. Good tires with good tread allow the tires to have adequate traction on the ground. A universal fitting system for tires and axels helps in increasing the life of both items. Many automobile manufacturers offer universal tire and axle fitments for their off-road vehicles. It is always best to have a universal fitment system installed to reduce the chances of premature tire or axle failures due to improper fit.

Bio-Rad Laboratories significantly contributing to the growth of the cell and gene therapy market with launch of Droplet Digital PCR (ddPCR) platforms

 

The growing prevalence of cardiovascular disease and cancer around the globe is primarily propelling the growth of the cell and gene therapy market. According to the World Health Organization (WHO), May 2017, around 17.9 million people died due to cardiovascular disease in 2016 globally, which accounts for 31% of all worldwide deaths. According to the same source, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020.

North America is expected to hold the dominant position in the global cell and gene therapy market and this is attributed to the growing prevalence of neurological disorders in the region. According to the U.S. Pharmacist Journal, January 2018, annually, around 1.2 million adults are diagnosed with early symptoms of brain disorders, of which 21% are due to Alzheimer’s disease, and the total number of new cases of Parkinson’s disease and traumatic brain injuries are around 135 million in the U.S. Moreover, growing research and development activities in the field of cell and gene therapy is again fostering the growth of the market. According to the Catalyst report, in December 2018, around 289 novel cell and gene therapies were in development for a variety of diseases, of which around 111 medicines were for cancer and around 28 medicines were for cardiovascular disease.

The cell and gene therapy field is ripe with opportunities and potential. Advances in technology are ushering in a whole new era in treating disease through personalized health care. The field now stands at a crossroads as it struggles to keep up with advances in molecular biology and pharmaceutical manufacturing capacity. The field now stands at a fork in the road as it battles the relentless march of technology and what it can do to the cell and gene therapy field.

The cell and gene production programs currently in development will usher in a sea change in the way we treat our diseases.

Key Developments:

1. In April 2021, Bio-Rad Laboratories, Inc. a global marketer in life science research and clinical diagnostic products announced the launch of two products for the Droplet Digital PCR (ddPCR) platforms to support the development and manufacture of safe and effective cell and gene therapies.

2. In January 2021, Ixaka (formerly Rexgenero) Launches as an Integrated Cell and Gene Therapy Company. The Company’s shareholders have funded the business with over £40 million in financing

3. In April 2021, Bayer has announced that it has expanded its cell and gene capabilities through the addition of a Cell Therapy Launch Facility

4. In January 2020, Lonza announced the process development roadmap for cell and gene therapies